Shares of AstraZeneca PLC (LON:AZN – Get Rating) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is £109.61 ($129.61).
AZN has been the subject of several analyst reports. The Goldman Sachs Group set a GBX 6,950 ($82.18) target price on shares of AstraZeneca in a report on Thursday, November 10th. Barclays reaffirmed an “overweight” rating and issued a £125 ($147.81) price target on shares of AstraZeneca in a research note on Friday, November 11th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Wednesday, November 16th. Berenberg Bank reissued a “buy” rating and set a £118 ($139.53) target price on shares of AstraZeneca in a research report on Tuesday. Finally, set a £120 ($141.89) price objective on shares of AstraZeneca in a research report on Monday, August 1st.
AstraZeneca Price Performance
AstraZeneca stock opened at £109.96 ($130.02) on Tuesday. The firm has a 50-day moving average price of £102.27 and a 200-day moving average price of £104.95. The firm has a market capitalization of £170.38 billion and a PE ratio of 10,064.22. The company has a current ratio of 0.81, a quick ratio of 0.59 and a debt-to-equity ratio of 88.97. AstraZeneca has a 12-month low of GBX 8,090.32 ($95.66) and a 12-month high of £115.40 ($136.46).
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.